Sponsored Content for Alison Coutts

Australian-based reproductive biotechnology company, Memphasys says it has received a research and development tax refund of about $1.3 million from the Australian Tax Office. The refund has been used to repay an R&D loan to Radium Capital of $849,000 plus interest of $46,621 and its net refund of $419,466 will be reinvested and used as working capital.

When all looked lost for a group of parent hopefuls in India, a groundbreaking piece of Australian medical technology developed by Memphasys has turned their dreams of the pitter-patter of tiny feet into reality. Memphasys confirmed today that after its Felix system led to a baby boy being born in India in April, another 10 families have now welcomed little ones into the world.

Reproductive technology specialist Memphasys has inked an exclusive five-year distribution deal with Vitrolife Japan KK – a subsidiary of the world-renowned Vitrolife Group – to sell its patented Felix system in Japan. Vitrolife is a world-leading global provider of medical devices, consumables and genetic testing services dedicated to the human IVF and reproductive health market, with a presence in more than 125 countries.

Reproductive biotechnology company Memphasys been granted two new patents by the Australian Patent Office for its flagship Felix system, ensuring that the integrity of the device is protected in all markets. Felix is a medical device that gently separates high-quality sperm from semen for use in IVF programs that combines membranes and a process involving an electrical charge called electrophoresis.

A women's hospital in India has delivered good news for reproductive biotechnology innovator Memphasys, reporting the first successful birth for the company's “Felix” sperm separation system. Memphasys has also scored a separate win with its first commercial sales in another key market – Japan. India offers Memphasys a $50 million opportunity, while Japan is twice that size.

Reproductive biotechnology company Memphasys is working with key opinion leaders in Japan and Canada to launch “in vivo” studies for its Felix System that aids IVF conception. In an update on its commercialisation activities, NSW-based Memphasys says the studies are precursors to potential commercial opportunities in Japan and Canada. Management adds that regulatory approval processes in China and the USA are also proceeding as planned.

Sydney biotechnology company Memphasys has passed another milestone by enrolling and treating the first couple in its new clinical study, en route to commercialising its unique reproductive technology device, Felix. The aim is to assess the safety and performance of Felix against two popular sperm selection techniques that isolate sperm from semen before they are used in assisted reproductive technologies.

Australian reproductive biotechnology company Memphasys is taking advantage of the worldwide easing of travel rules to turbocharge its trademarked Felix System into global in-vitro fertilisation markets. Memphasys has announced a targeted sales push, with the first pitch aimed at India, where Felix late last year scored its breakthrough commercial sales deal.

Trailblazing biotech Memphasys has achieved a crucial step in the rollout of its IVF sperm separation technology after winning a draft ISO for its quality management system for manufacturing medical devices. Memphasys said the ISO 13485 certificate will assist with selling medical devices in high regulatory markets such as Australia, Europe and China and it is an important step for product accreditation and acceptance by customers.

In a milestone achievement, Memphasys has landed the first sale of the company's revolutionary trademarked Felix bio-separation technology placed by a women's centre in Coimbatore, India. The centre will be the first to use the system for clinical IVF with the order including a Felix console plus an initial supply of single-use cartridges. The Felix business model is based on recurring sales of the cartridges so the initial sale may represent ongoing business.

Memphasys is rapidly hurtling towards commercialising with its “Felix” bio-separation IVF technology with clinical trials set to commence to assess embryo fertilisation efficacy in patients at four Monash IVF Australian clinics. 104 couples are anticipated to commence IVF trials in March 2022 with results expected to support regulatory filings and international commercial sales.